HBPCF (Helix BioPharma) 3-1 Month Momentum %: -1.16% (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma 3-1 Month Momentum %?

Helix BioPharma HBPCF 28 3-1 Month Momentum % is -1.16% as of Jul. 18, 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,389 Biotechnology companies, Helix BioPharma ranks worse than 71.06% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-18), Helix BioPharma's 3-1 Month Momentum % is -1.16%.

The industry rank for Helix BioPharma's 3-1 Month Momentum % or its related term are showing as below:

HBPCF's 3-1 Month Momentum % is ranked worse than
71.06% of 1389 companies
in the Biotechnology industry
Industry Median: -13.25 vs HBPCF: -1.16

Helix BioPharma  (OTCPK:HBPCF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Helix BioPharma 3-1 Month Momentum % Related Terms

HBPCF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Helix BioPharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's 3-1 Month Momentum % falls into.


HBPCF
28GF Score
Helix BioPharma Corp HBPCF
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma  (OTCPK:HBPCF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -1.16% mean?
Helix BioPharma (HBPCF) has a 3-1 Month Momentum % of -1.16% as of Jul. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #987 out of 1389 companies in the Biotechnology industry, placing it in the top 71.1%.
Is Helix BioPharma's 3-1 Month Momentum % too high?
Helix BioPharma's current 3-1 Month Momentum % is -1.16%. Based on the distribution chart, Helix BioPharma ranks #987 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #987 out of 1389 companies for 3-1 Month Momentum %. This places Helix BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current 3-1 Month Momentum % is -1.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current 3-1 Month Momentum % of -1.16%. The current 3-1 Month Momentum % is -1.16%. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current 3-1 Month Momentum % is -1.16% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price